Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Percent of Patients alive after 4 years (Overall Survival)
The status of each patient alive/not alive is surveyed every 3 months in year 1+2 and every 6 months in year 3+4 after randomisation.
Martin Bornhaeuser, Prof. (MD)
Universitätsklinikum Dresden, Medizinische Klinik und Poliklinik I, Germany
Germany: Ethics Commission